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Abstract: The increase in serotonin (5-HT) neurotransmission is considered to be one of the most efficacious medical ap-
proach to depression and its related disorders. The selective serotonin reuptake inhibitors (SSRIs) represent the most 
widely antidepressive drugs utilized in the medical treatment of depressed patients. Currently available SSRIs include 
fluoxetine, sertraline, paroxetine, fluvoxamine, citalopram and escitalopram. The primary SSRIs pharmacological action’s 
mechanism consists in the presynaptic inhibition on the serotonin reuptake, with an increased availability of this amine 
into the synaptic cleft. Serotonin produces its effects as a consequence of interactions with appropriate receptors. Seven 
distinct families of 5-HT receptors have been identified (5-HT1 to 5-HT7), and subpopulations have been described for 
several of these. The interaction between serotonin and post-synaptic receptors mediates a wide range of functions. The 
SSRIs have a very favorable safety profile, although clinical signs of several unexpected pathologic events are often mis-
diagnosed, in particular, those regarding the eye. In all cases reported in the literature the angle-closure glaucoma repre-
sents the most important SSRIs-related ocular adverse event. Thus, it is not quite hazardous to hypothesize that also the 
other reported and unspecified visual disturbances could be attributed - at least in some cases - to IOP modifications. The 
knowledge of SSRIs individual tolerability, angle-closure predisposition and critical IOP could be important goals able to 
avoid further and more dangerous ocular side effects. 
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1. SEROTONIN AND 5-HT RECEPTORS 
  Serotonin (5-hydroxytryptamine, 5-HT) is widely dis-
tributed in animals and plants, occurring in vertebrates, 
fruits, nuts, and venoms. In 1948, Rapport and co-workers 
were the first to isolate this vasoconstrictor, released from 
platelets in clotting blood, which subsequently named sero-
tonin [119]. 5-HT is a biogenic monoamine that produces its 
effects through a variety of membrane-bound receptors. Al-
though serotonin may be obtained from a variety of dietary 
sources, in humans endogenous 5-HT is synthesized in situ 
from tryptophan, its amino acid precursor, through two steps. 
First, tryptophan is hydroxylated to 5-hydroxytryptophan by 
tryptophan hydroxylase; then, 5-hydroxytryptophan is decar-
boxylated to 5-hydroxytryptamine (Fig. 1). The hydroxyla-
tion of tryptophan is the rate-limiting step in this process. 
Tryptophan hydroxylase is only half saturated with its sub-
strate, which suggests that increasing the level of tryptophan 
should increase the 5-HT synthesis [30, 124]. Both dietary 
and endogenous 5-HT are rapidly metabolized and inacti-
vated by monoamine oxidase (MAO) and aldehyde dehydro-
genase to the major metabolite, 5-hydroxy-indoleacetic acid 
(5-HIAA), even if most of the 5-HT released into the post-
synaptic space is removed by the neuron through a re-uptake 
mechanism (Fig. 2). There are two important types of MAO, 
which possess different preferential affinity to serotonin 
(MAO-A) or dopamine (MAO-B) [124]. 5-HT is not easily  
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Fig. (1). The biosynthesis of serotonin from the amino acid trypto-
phan. 
transported across the blood-brain barrier; conversely, tryp-
tophan is actively transported across the blood-brain barrier 
from circulation [25]. 
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Fig. (2). The catabolism of serotonin. 
  Despite its relatively simple chemical structure, serotonin 
exhibits very complex properties. Based on the similarity 
with noradrenaline (NA) and dopamine, it is not surprising 
that 5-HT, like its catecholamine counterparts, possesses a 
broad spectrum of different psychological effects. The ac-
tions of 5-HT are realized by three major mechanisms: i) 
diffusion; ii) metabolism; and iii) uptake back into the synap-
tic cleft, through the action of specific amine membrane 
transported systems. Thus, the actions of 5-HT can be theo-
retically modulated by agents that play a role at different 
steps: (I) stimulate or inhibit its biosynthesis; (II) block its 
storage; (III) stimulate or inhibit its release; (IV) mimic or 
inhibit its actions at its various post-synaptic receptors; (V) 
inhibit its uptake back into the nerve terminal; (VI) affect its 
metabolism [51, 124]. 
  Serotonin has been found both in several non-neuronal 
districts of the human body (i.e. blood, cardiovascular sys-
tem, gastrointestinal tract and eye), and in the central and 
peripheral nervous systems (CNS/PNS), where it works as 
neurotransmitter or hormone. 5-HT is involved in the regula-
tion of numerous physiological processes. Serotonergic neu-
rons, at the level of the CNS, are found in the raphe nuclei of 
the brainstem/pons region; from here, 5-HT is able to influ-
ence most areas of the CNS, modulating a wide variety of 
sensory, motor, and cortical functions [101]. 5-HT has been 
shown to reset or phase-shift the circadian rhythm, control-
ling the endogenous clock located at the levels of the su-
prachiasmatic nuclei of the hypothalamus. In the PNS, sero-
tonin is involved in such different functions as the initiation 
of activity in primary afferent nociceptors; 5-HT is an effec-
tor on various types of smooth muscle, functioning also at 
the level of ciliary muscle and sphincter of the pupil. This 
monoamine is implicated in the regulation of enteric re-
flexes, increasing the gastrointestinal motility, in the modula-
tion of vascular smooth muscle contraction, constricting the 
large vessels and/or producing both contraction and relaxa-
tion of coronary artery in mammals. Moreover, 5-HT repre-
sents a precursor for melatonin production in the pineal 
gland and in the lens; it is an agent that contributes to the 
modulation of platelet shape change, enhancing the platelet 
aggregation (homeostasis), and concurs to the regulation of 
lymphocyte cyto-toxicity and phagocytosis [2, 51, 66, 108, 
112, 124]. 
  Adequate serotonin levels regulate sleep, mood, food 
intake and pain tolerance; whereas significant systemic or 
localized 5-HT alterations are thought to produce insomnia, 
increased food cravings, increased sensitivity to pain, poor 
body-temperature regulation, depressive and aggressive be-
haviors. Thus, 5-HT has been implicated in the etiology of 
miscellaneous physiopathologic conditions and diseases, i.e. 
depression, anxiety, social phobia, schizophrenia, obsessive-
compulsive and panic disorders, migraine, intraocular pres-
sure (IOP) modification, systemic hypertension, pulmonary 
hypertension, eating disorders, vomiting, and irritable bowel 
syndrome [28, 51, 66, 73, 108, 124, 132, 137, 138]. 
  The chemical neurotransmitter serotonin produces its 
effects as a consequence of interactions with appropriate 
receptors. 5-HT is synthesized in neurons and stored in vesi-
cles. Upon a nerve impulse, it is released into the synaptic 
cleft, where it interacts with multiple post-synaptic receptors, 
mediating a wide range of physiological functions. Seven 
distinct families of 5-HT receptors have been identified (5-
HT1 to 5-HT7), and subpopulations have been described for 
several of these (Table 1). The 5-HT receptor subtypes are 
expressed in distinct but often overlapping patterns and are 
coupled to different transmembrane-signaling mechanisms. 
Four 5-HT receptor families with defined functions, 5-HT1 to 
5-HT4, are currently recognized. With the exception of the 5-
HT3 receptor, the other subtypes of these receptors belong to 
the G-protein-coupled receptor (GPCR) superfamily, and are 
related to a predicted membrane topology which is com-
posed of an extracellular N-terminal segment, linked to an 
intracellular C terminus by seven transmembrane-spanning 
segments. Otherwise, the 5-HT3 receptor is a ligand-gated 
ion channel that gates Na
+ and K
+ and has a predicted mem-
brane topology similar to that of the nicotine cholinergic 
receptor. In the last two decades, most of the currently 
known 5-HT receptor populations have been identified and a 
high number of papers in the serotonin area has been pub-
lished. These investigations have reported the cloning of 
several receptor populations previously known but not yet 
cloned, the development of novel agonists and antagonists 
with greater receptor subtypes selectivity, additional molecu-
lar biology studies (i.e. site-directed mutagenesis), and new 
pharmacologic and clinical findings. Evidence continues to 
emerge emphasizing the role of 5-HT receptors in various 
neuropsychiatric disorders. Anxiety, depression, schizophre-
nia, migraine, and drug abuse are at the top of this list. 5-HT 
receptors may also be involved in appetite control, aggres-
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Table 1.  Nomenclature Used to Identify Various Populations and Subpopulations of Serotonin Receptors (5-HT Receptor Sub-
types) [2, 5, 7] 
Receptor 
Structural 
Family 
Signal Transduc-
tion 
Localization  Function  Comments 
5-HT1A GPCR  Inhibition  of  AC 
Hippocampus, Septum, 
Amygdala, Cortical limbic areas, 
Raphe nuclei 
Autoreceptor 
Cloned and pharmacological 5-
HT1A sites. 
5-HT1B GPCR  Inhibition  of  AC 
Basal and Trigeminal ganglia, 
Striatum, Frontal cortex 
Cerebral arteries and other vas-
cular tissues 
Autoreceptor 
Rodent homologue of human 5-
HT1D receptors. 
Basal and Trigeminal ganglia  Unknown 
5-HT1D GPCR  Inhibition  of  AC 
Cranial blood vessels  Vasoconstriction 
Newer name: 5-HT1B; 
a mouse homologue of human 5-
HT1D receptors; 
sites identified in binding studies 
using brains homogenates; 
5-HT1D and 5-HT1D (cloned hu-
man 5-HT1D subpopulations). 
5-ht1E  GPCR  Inhibition of AC  Cerebral cortex, Striatum  Unknown 
Newer name: 5-ht1E; 
sites identified in binding studies 
using brain homogenates; 
5-ht1Ea (an alternate name for cloned 
human 5-ht1E receptors). 
Dorsal raphe, Hippocampus, 
Striatum, Cerebral cortex, 
Thalamus, Hypothalamus 
Unknown 
5-ht1F GPCR  Inhibition  of  AC 
Uterus, Mesentery  Vasoconstriction 
A cloned human 5-HT1-like recep-
tor population. 
Cerebral cortex, Claustrum, 
Basal ganglia 
Neuronal excitation 
Smooth muscle  Contraction 
5-HT2A 
(D receptor) 
GPCR Activation  of  PLC 
Platelets Platelet  aggregation 
Newer name: 5-HT2A; 
original "5-HT2" (5-HT2) receptors 
Cerebellum, Lateral septum, 
Hypothalamus, Medial 
amygdala 
Unknown 
Stomach fundus  Contraction 
5-HT2B GPCR 
Activation of PLC 
(Other unknown) 
Blood vessels  Vasodilatation 
Newer name: 5-HT2B; 
5-HT2-like receptors in rat fundus 
5-HT2C  GPCR  Activation of PLC  Choroid plexus  Vasodilatation 
Newer name: 5-HT2C; 
original "5-HT1C" (5-HT2) recep-
tors. 
5-HT3 
(M receptor) 
5-HT-GIC 
Ligand-gated ion 
channel 
Area postrema, Enthorinal and 
Frontal cortex, Hippocampus, 
Solitary Tract, Amygdala 
Peripheral pre- and post-
ganglionic autonomic neurons, 
Sensory nervous system, Gastro-
intestinal tract 
Neuronal excitation  An ion channel receptor. 296    Current Neuropharmacology, 2008, Vol. 6, No. 4  Costagliola et al. 
(Table 1. Contd….) 
Receptor 
Structural 
Family 
Signal  
Transduction 
Localization  Function  Comments 
5-HT4  GPCR  Activation of AC 
Hippocampus, Colliculi, Nu-
cleus accumbens 
Gastrointestinal tract, Vascular 
smooth muscle 
Neuronal excitation 
5-HT4 population originally de-
scribed in functional studies; 
5-HT4s (short form of cloned rat 5-
HT4 receptors); 
5-HT4L (long form of cloned rat 5-
HT4 receptors). 
5-ht5A GPCR  Inhibition  of  AC 
5-ht5B Unknown  Unknown 
Hypothalamus, Hippocampus, 
Corpus callosum, Fimbria, Ce-
rebral ventricles, Glia 
Unknown 
Cloned mouse, rat and human 5-ht5 
or 5-ht5A-like receptors. 
5-ht6  GPCR  Activation of AC 
Caudate nucleus, Striatum, 
Amygdala, Nucleus accumbens, 
Hippocampus, Cerebral cortex 
and Olfactory tubercle 
Unknown 
Cloned rat and human 5-HT recep-
tors. 
5-HT7 GPCR  Activation  of  AC 
Cerebral cortex, Thalamic nu-
clei, Sensory nuclei, Substantia 
nigra, Hypothalamus, Raphe 
nuclei 
Vascular tissues, Smooth muscle 
(ileum) 
Unknown 
Cloned rat, mouse, guinea pig and 
human 5-HT receptors; 
original "5-HT1-like" receptors. 
Legend: GPCR, G protein-coupled Receptor; 5-HT-GIC, 5-HT-gated ion channel; AC, adenylate cyclase; PLC, phospholipase C. 
 
sion, sexual behavior, and cardiovascular disorders. Re-
cently, working with always more specific methodological 
approach it has been documented that some medications, 
previously considered selective, are not as selective as origi-
nally hypothesized. In this way, it has been possible to un-
derstand both the therapeutic actions and some paradox ef-
fects related to the administration of these substances, as 
well as the occurrence of, otherwise unexplained, side ef-
fects. The multiple 5-HT receptor subtypes cloned to date 
represent one of the most complex family of known neuro-
transmitter receptors with, at least, fourteen distinct members 
[51, 66, 124]. 
2. ROLE OF SEROTONIN IN THE EYE 
  In the mammalian eye (Fig. 3), the distribution and the 
functions of serotonin have been mainly investigated by Os-
borne and his group at the Nuffield Laboratory of Ophthal-
mology in Oxford. Their researches represent a milestone to 
understand the physiopathology of this biogenic monoamine 
and have been the substantial core to build this review arti-
cle. Serotonin has been found in different ocular structures 
depending on both CNS and PNS. Since 1948 when sero-
tonin was first isolated, identified and synthesized, there has 
been an exponential growth in the information available on 
its biochemical, physiologic, and behavioral effects. Histori-
cally, initial researches were focused to define the pathways 
for synthesis and degradation of 5-HT and to develop of 
drugs interacting with these processes. In more recent times, 
the discovery and widespread clinical use of selective anti-
depressive medications, the pre-clinical delineation of the 
multiple 5-HT receptor subtypes together with their coupling 
to intracellular messenger systems, and the development of 
compounds selectively acting on these systems, have cata-
lyzed an explosion of new information in this field. It is now 
clear that the 5-HT system is involved in a multitude of 
physiologic and behavioral processes. Shortly after the dis-
covery of 5-HT as a potent vasoconstrictor agent in blood 
serum [119], this monoamine was found in many other tis-
sues, including several districts of the mammalian eye [45, 
102, 103, 108, 109, 129, 137, 138]. This led to the sugges-
tion that serotonin could function as a neurotransmitter 
and/or a hormone in various central and peripheral mammal-
ian tissues. The mammalian eye contains both central and 
peripheral neuronal tissues. The retina, as an out-growth of 
the brain, is considered as a part of the CNS. The other parts 
of the eye, namely the cornea, sclera, iris, ciliary muscle and 
processes, retinal pigment epithelium and choroid, receiving 
nerves that are derived from the PNS, as more closely perti-
nent to them [108]. The discovery of receptors for serotonin 
within the eye strongly suggests that 5-HT plays a functional 
role in the various ocular tissues (Table 2). The diverse ac-
tion of 5-HT are mediated by a variety of specific receptors 
and, as pointed out in the specific section, seven class of 
these receptors have been recognized on the basis of struc-
tural, transductional and functional characteristics [28, 108]. 
Detection of 5HT receptor subtype mRNAs in numerous 
human ocular tissues has been successfully performed by 
Sharif and Senchyna [129]. While it is difficult to associate 
these observations with functional evidence for the existence 
of the various 5HT receptors in these tissues in every case, 
these data provide a foundation for future research to dis-
cover the physiological and pharmacological relevance of the 
5HT receptors in the human ocular tissues. 
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2.1. Cornea 
  The presence of functional serotonergic receptors in the 
rabbit cornea was firstly postulated by Neufeld and co-
workers [98]. These authors have demonstrated that sero-
tonin increases the level of cAMP in incubated rabbit cor-
neas and that the corneal epithelium contains specific sero-
tonergic receptors. These specific serotonergic receptors are 
present in the corneal epithelium and their activation by sero-
tonin released from serotonergic neurons increases both the 
level of cAMP at the level of stromal cells and the chloride 
transport at the level of corneal epithelium [73]. The sero-
tonergic receptors must be at a location posterior to that of 
the -adrenergic receptors, which are on the anterior-surface 
of the apical cells. The serotonin response is partially inhib-
ited by the -adrenergic antagonist, timolol [105]. The inves-
tigations conducted in the experimental models strongly sug-
gest that in the cornea exist at least two classes of serotoner-
gic receptors: the first responsible for increased levels of 
cAMP, located at the level of stromal cells; whereas the sec-
ond responds to serotonin by increasing chloride transport in 
the epithelial cells, without a concomitant elevation of cAMP 
levels [73, 96, 105, 109]. Chidlow and co-workers did not 
found evidence for the existence of 5-HT1A and 5-HT7 recep-
tors in the cornea which, on the contrary, are widely distrib-
uted in other ocular tissues [28]. It can be hypothesized that 
5-HT4 and 5-HT6 subtypes are present in the corneal stroma; 
in fact, the effect of 5-HT in the stroma is antagonized by 
methysergide [105], a ligand known to be inactive on 5-HT4 
receptors [99], and only weakly effective on 5-HT6 receptors 
[42]. Experimental evidences have demonstrated the implica-
tion of 5-HT2, 5-HT3 and 5-HT4 serotonin receptor subtypes 
in the chloride transport in various tissues [28, 58, 90], thus 
it could be accepted that also in the corneal epithelium these 
receptors could be represent the most obvious candidates for 
the chloride transport, especially the 5-HT2 subtype [56] 
playing their major role in the regulation of fluid transport or 
corneal homeostasis. 
2.2. Iris and Ciliary Body 
  Serotonin is present in mammalian iris-ciliary body com-
plex (ICB) at higher concentration that in non-mammalian 
species [5, 45, 73, 129, 137]. Moreover, the presence of sero-
tonergic nerves has been demonstrated in studies conducted 
on the ICB of various species [102, 137, 138]. Experimental 
evidence and radioligand analyses have defined the presence 
at this level of three different types of serotonin receptors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Schematic horizontal section of the human eye: anatomic structures and vasculature. 
Legend: a, cornea; b, iris; c, lens; d; suspensory ligament of the lens (ciliary zonule of Zinn); e, ora serrata; f, medial rectus muscle of the 
eye; g, retina; h, sclera; i, choroid; l, optic nerve head; m, central fovea of the macula; n, lamina cribrosa; o, irido-corneal angle. 
1, minor circle of iris; 2, Schlemm's channel; 3, major circle of iris; 4, iuxtalimbic conjunctival vessels; ciliary circle; 6, anterior ciliary ar-
tery; 7, anterior ciliary arteries and veins; 8, vorticose vein; 9, retinal microvasculature; 10, episcleral arteries and veins; 11, long posterior 
ciliary artery; 12, short posterior ciliary arteries; 13, central retinal artery and vein; 14, perioptic nerve arteriolar anastomoses (circle of Haller 
and Zinn); 15, pial microarterioles. 298    Current Neuropharmacology, 2008, Vol. 6, No. 4  Costagliola et al. 
[10, 28, 85, 136, 137], i.e. 5-HT1A, 5-HT2A/2C and 5-HT7 [98], 
one linked to a stimulation of inositol phosphates (5-HT2 
subtype), while the others two are linked to cAMP activity.  
 
The plausibility of the existence of more than one 5-HT re-
ceptor type in the ciliary body is confirmed by intraocular 
pressure (IOP) experiments. Topical application of serotonin 
 
Table 2.  Distribution of 5-HT Receptor Subtypes in the Ocular Tissues and in the Vascular Structures of the Eye 
District 
Receptor Sub-
type 
Signal Transduction  Localization  Comments 
5-HT2  Activation of PLC  Corneal epithelium 
(5-HT3) 
(5-HT4) 
(Ligand-gated ion chan-
nel) 
(Activation of AC) 
Corneal epithelium 
C
o
r
n
e
a
 
5-HT4 and 5-HT6  Activation of AC  Corneal stromal cells 
These receptors were investigated in the cornea of the 
rabbit; 
serotonin response is partially inhibited by the -
adrenergic antagonist (timolol); 
the serotonin role in corneal structures is largely un-
known. 
5-HT1A Inhibition  of  AC 
Epithelial cell layer (pigmented 
and non-pigmented) of the pars 
plicata region of the ciliary proc-
esses 
Reduced production of aqueous humor (regulation of the 
intraocular pressure level). 
5-HT2A and 5-
HT2C 
Activation of PLC   Iris-ciliary body complex 
This action is partially counteracted by 5-HT2 antago-
nists, such as ketanserin, which reduces the intraocular 
pressure. 
Sphincter of the pupil 
Relaxation of this smooth muscle (mydriasis); 
miosis is induced by the intravitreal injection of a sero-
tonergic neurotoxin (5, 6-dihydroxytryptamine). 
I
r
i
s
 
a
n
d
 
c
i
l
i
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r
y
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o
d
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5-HT7 Activation  of  AC 
Epithelial cell layer (pigmented 
and non-pigmented) of the pars 
plicata region of the ciliary proc-
esses 
Augmented production of aqueous humor (regulation of 
the intraocular pressure level). 
5-HT2 Activation  of  PLC  Epithelial cells and other cell 
populations of the lens 
5-HT3  Ligand-gated ion channel  Nuclear cell lines of the lens 
These receptors were investigated in the lens of animal 
models; 
serotonin is synthesized in situ and transported from the 
aqueous humor, inhibiting ATPase in lens epithelium 
(organogenesis and preservation of transparence). 
L
e
n
s
 
(5-HT1A and 5-
HT7) 
(Regulation of AC activ-
ity) 
Epithelial cells of the lens  For these receptors low levels of messenger ribonucleic 
acid were detected. 
5-HT1A Inhibition  of  AC  Ganglion cells, Retinal pigment 
epithelium 
5-HT2A Activation  of  PLC 
Terminal part of the photorecep-
tors and rod bipolar cells, Retinal 
pigment epithelium 
5-HT3  Ligand-gated ion channel  Terminal part of the rod 
R
e
t
i
n
a
 
5-HT7  Activation of AC  Ganglion cells 
In the mammalian retina serotonergic system may be a 
common feature despite the low 5-HT levels; 
visual processing; 
ganglion cells apoptosis modulation; 
although the 5-HT functions in the retinal pigment epi-
thelium are unknown, it probably has an extensive range 
of metabolic actions mediated by cAMP. 
Unknown Unknown  Unknown 
C
R
A
 
a
n
d
 
C
A
 
5-HT2  Activation of PLC  Endothelial cells 
In atherosclerotic monkeys 5-HT caused vasospasm of 
extraocular arteries but not of the retinal arterioles; 
in patients with normal pressure glaucoma contractile 
responses to 5-HT and endothelin-1 are abnormal for a 
dysfunction of the systemic vascular endothelium. 
Legend: AC, adenylate cyclase; PLC, phospholipase C; cAMP, adenylate cyclase; CRA, central retinal artery; CA, ciliary artery. Selective Serotonin Reuptake Inhibitors  Current Neuropharmacology, 2008, Vol. 6, No. 4    299 
has been reported to both elevate [84] and lower [88] IOP in 
rabbit. A large number of reports have shown that serotonin 
agonists and antagonists can produce increases and decreases 
in IOP when given orally, topically to the eye or when they 
are directly injected in the anterior chamber [10, 26, 34, 35, 
64, 75, 84, 87, 88, 112, 113, 126, 136, 137]. A rationale for 
such apparently contradictory results may be due to the dif-
ferent sites of action, i.e. which class of serotonin receptor is 
activated. In fact, in rabbit the administration of 5-methyl-
urapidil (a combined 5-HT1A agonist/1 adrenoreceptor an-
tagonist) and 8-OH-DPAT (8-hydroxydypropylaminotetralin, 
a 5HT1A agonist) reduces IOP, while the administration of 5-
CT (5-carboxamidotryptamine, a 5-HT1A and 5-HT7 agonist) 
increases IOP [36, 84, 99]. 
  Chidlow, Le Corre and Osborne [28] have recently dem-
onstrated that, in section taken through the whole eye and 
ciliary body, prominent 5-HT1A and 5-HT7 receptor messen-
ger ribonucleic acid signals were obtained. These signals 
were evident in both the pigmented and non-pigmented 
epithelial cell layers of the pars plicata region of the ciliary 
processes, but not in the pars plana or in the ciliary muscula-
ture. 5-HT1A and 5-HT7 signals were apparent in the poste-
rior processes but not in the iris processes. The presence of 
both receptors in the ciliary body would certainly provide an 
explanation for the shallow displacement curves observed in 
[
3H]5-HT binding studies with the tissue [110], since this 
ligand can be used to label both receptors. Because the cil-
iary epithelium of the pars plicata is responsible for the se-
cretion of aqueous humor, an obvious function for these two 
receptors would be an involvement in the control of aqueous 
production and, consequently, of the IOP level. Further, the 
almost identical distribution of the 5-HT1A and 5-HT7 mes-
sengers ribonucleic acid indicate that the receptors may be 
co-localized in epithelial cells. The presence of two serotonin 
receptors with opposing effects on cAMP in the same cell 
layer prompts the suggestion that they could act antagonisti-
cally. The agonism of 5-HT1A receptors, negatively coupled 
to cAMP, reduces IOP by decreasing the production of 
aqueous humor, like -receptor antagonists which, diminish-
ing the content of cAMP at the postjunctional site, lowers the 
aqueous humor secretion with a consequent decrease in IOP 
[98]. On the contrary, the administration of 5-CT induces a 
rise in IOP, which is partly or entirely caused by an increase 
in aqueous humor secretion mediated by 5-HT7 receptors 
[84]. 
  The other type of serotonin receptor present in the ICB is 
a 5-HT2 type. Serotonin stimulates the accumulation of inosi-
tol phosphates in the ICB and this effect is partially counter-
acted by the 5-HT2 antagonists ketanserin, methysergide and 
mianserin [98]. Studies with ketanserin have demonstrated 
that, when orally or topically applied, it lowers IOP in ani-
mals, healthy volunteers and in glaucomatous patients [26, 
34, 37, 64, 75, 88, 113, 126]. It has been emphasized that 
ketanserin also possesses an affinity for 1-adrenoreceptors 
[27, 36, 139], and for this reason the effects of ketanserin on 
IOP may not be entirely caused by its action on 5-HT2 recep-
tors. However, data from human studies conducted after oral 
or topical administration of ketanserin, in which were deter-
mined the variations of IOP, total outflow facility and pupil 
diameter, demonstrated that the 1-adrenoreceptor blocking 
effect exerted by ketanserin should represent a further aspect 
of its mechanism of action, probably due to a functional 
sharing of these receptors [64, 87]. Lastly, already in 1992 
Martin and co-workers showed the occurrence of a signifi-
cant correlation between the content of serotonin in the 
aqueous humor and IOP in the human eye [85]. 
  In 1981, Moro and his collaborators found that in-
travitreal injection of 5, 6-dihydroxytryptamine, a serotoner-
gic neurotoxin, causes miosis [91]. The identification of 5-
HT7, but not of 5-HT1 receptors in the rabbit iris, suggests 
that this population of serotonergic receptors is involved in 
the relaxation of the sphincter of the pupil. In fact, one of the 
function correlate to 5-HT7 receptor activation includes 
smooth muscle relaxation observed in a variety of isolated
 
tissue preparations, in which elevation of cAMP concentra-
tion
 was also detected [3, 44]. Further evidence for the me-
diation of the relaxant
  response  via the 5-HT7 receptor is 
provided by the localization
 of messenger ribonucleic acid 
transcripts encoding the 5-HT7 receptor in many blood
 ves-
sels [67]. This hypothesized mechanism of action is also 
supported by the fact that various other receptor types, also 
positively coupled to cAMP, in the iris cause relaxation of 
the sphincter muscle [1, 28]. 
2.3. Lens 
  The presence of serotonin and its receptors in the lens has 
not been extensively investigated, even is it has been ascer-
tained that 5-HT is both synthesized in situ and transported 
from the aqueous humor. Serotonin inhibits the ATPase at 
the level of lens epithelium, and the physiological activity of 
this membrane enzyme represents a crucial point in the 
maintenance of lens transparence [24]. More recently, the 
administration of a selective 5-HT3 antagonist to pregnant 
rats has been responsible for the development of nuclear 
cataract in the offspring. These findings seem to suggest that 
5-HT3 receptors play a significant role during the lens or-
ganogenesis, throughout a triggering effect on the cation 
channels [66, 78]. Evidence for the presence of phosphoi-
nositide cycle and its involvement in cellular signal transduc-
tion in the rabbit lens has been obtained by Vivekanandan 
and Lou [140]. These researches demonstrated that lens epi-
thelium cells, like other cell types, possess a complete and 
functional phosphoinositide cycle, which is activated when 
the lens cells are exposed to serotonin or to other substances 
like calcium, epithelium growth factor and glucagon [140]. It 
is conceivable to suppose a role for the 5-HT2 receptor class 
in the regulation of this mechanism. Lastly, Chidlow and co-
workers has found very low levels in the lens of messenger 
ribonucleic acid for 5-HT1A and 5-HT7 receptors, indicating 
that these receptors are expressed in epithelium [28]. 
2.4. Retina 
  Although 5-HT is found in the mammalian retina only at 
low levels, considerable evidence suggests that it plays a role 
in visual processing. Pharmacological experiments indicate 
that numerous receptors for 5-HT are present in the mam-
malian retina [115, 116]. In the rabbit, where the most exten-
sive study of mammalian retina has been performed, early 
radioligand binding experiments provided evidence for the 
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addition, 5-HT3 binding sites have been characterized in the 
rabbit retina [6], and two subunits for this receptor (5-HT3A 
and 5-HT3B) have been identified both in the nervous system 
of rabbit and rat, and in human retina. Further immunoreac-
tivity studies have demonstrated that this receptor is local-
ized specifically to the rod photoreceptor terminals of all 
three species [116]. Conflicting data existed about whether 
the 5-HT1A receptor family was positively [9, 21, 28, 99] or 
negatively coupled to cAMP [43]. This question was solved 
by the cloning of the 5-HT7 receptor which shows a pharma-
cologic profile similar to that of the 5-HT1A receptor, and is 
positively coupled to cAMP [81, 122]. These findings have 
allowed the identification of 5-HT7 receptor also in the retina 
[106, 117], confirming the suggestion that the retina seroton-
ergic system may be a common feature in mammals despite 
the fact that the 5-HT levels are extremely low. 
  Neuro-pharmacological studies have shown that the acti-
vation of 5-HT1A and 5-HT2 receptors affect visual process-
ing [19, 20, 28], and 5-HT2A receptors are associated with 
terminals of the photoreceptors and rod bipolar cells in the 
rabbit retina [117]. Recently, Osborne and co-workers have 
focused their attention on the possible role of serotonergic 
receptors of the retina in the modulation of the ganglion cells 
death, which plays a key role in the progression of the field 
loss in glaucomatous patients [110]. These authors have ex-
perimentally demonstrated that 5-HT1A agonists are able to 
reduce IOP, through a 5-HT1A receptors stimulation of the 
ciliary processes [29, 98], and to attenuate ganglion cell 
death induced by increased IOP, through interaction with 
membrane sodium channels and/or 5-HT7 receptors [104, 
131, 134]. The clinical implications of these experimental 
evidence is yet to be demonstrated, but this studies seem to 
indicate that 5-HT1A agonists could become a new class of 
drugs for the treatment of glaucoma in a near future [107]. 
  The studies conducted by Nash, Osborne and co-workers 
have documented the presence of 5-HT2A receptors at the 
level of the cultured rat retinal pigment epithelium cells. 
Moreover, human retinal pigment epithelium cells possess 
functional 5-HT1A receptors which inhibit the cAMP produc-
tion; even if the role of these receptors is unknown, the ex-
tensive range of metabolic actions mediated in vitro by 
cAMP indicates that they may modulate several cellular 
functions of the retinal pigment epithelium [94 - 96]. 
2.5. Vascular Structures 
  Before considering the interactions among serotonin, 
vascular compartments controlling the blood supply to the 
eye, and their hemodynamic characteristics, it is important to 
highlight that several structural differences exist between the 
extraocular vessels and the intraocular microvessels. Ex-
traocular vasculature derives from the internal carotid artery 
including ophthalmic, lachrymal and ciliary arteries together 
with their correspondent draining venous structures. Some 
ramifications of these arteries, i.e. short and long posterior 
ciliary arteries, anterior ciliary arteries and central retinal 
artery, perforate the sclera or the optic nerve to supply the 
iris, ciliary body, retina, choroid, anterior and posterior re-
gions of the optic nerve providing, respectively, several pe-
culiar microvascular compartments: arterial circles of the 
iris, ciliary process, retinal vasculature, choroidal lobules, 
perioptic nerve arteriolar anastomoses (circle of Haller and 
Zinn) and pial microarterioles [100]. 
  In experimental models, the role of 5-HT has been inves-
tigated considering its effects in some extraocular vessels, 
such as central retinal artery, ciliary artery and posterior cil-
iary arteries. These studies have documented a serotonin-
induced vasoconstriction at the level of the posterior ocular 
segment [14, 57, 62]. In particular, Haefliger, Flammer and 
Luscher have demonstrated, in the porcine eye, this vaso-
spasm was inhibited by ketanserin (an 1-adrenoceptor and 
5-HT2 receptor antagonist) [57]. Hayreh and co-workers 
findings revealed that, although serotonin has no significant 
effect on ocular vessels of normal monkeys, in atheroscle-
rotic ones it caused vasospasm of central retinal artery and/or 
posterior ciliary artery without inducing vasoconstriction of 
the retinal arterioles [60, 62]. More recently, in patients af-
fected by normal pressure glaucoma, it has been identified a 
dysfunction of the systemic vascular endothelium in the 
course of its contractile responses to 5-HT and endothelin-1, 
suggesting alterations of the receptor populations on this 
endothelium [22]. 
3. PHYSIOPATHOLOGY OF THE INTRAOCULAR 
PRESSURE 
  Aqueous humor is a clear liquid contained into the ante-
rior and posterior chambers of the eye (Figs. 3 and 4). It is 
formed continuously, at a rate of approximately 2-3 μl/min, 
by the ciliary body in the posterior chamber [41]. Ciliary 
body is divided into two parts: posterior and anterior. The 
posterior part constitutes the flat ciliary ring and, because of 
its morphology, is also called pars plana ciliaris; the anterior 
one, which plays the active role in the secretion of aqueous 
humor, is made out of approximately 70 radial plicae, i.e. the 
ciliary processes. These are made of vascular bundles sur-
rounded by a stroma of loose connective tissue and covered 
by two layers of ciliary epithelium. More in details, each 
ciliary process consists of a pigmented layer, which is con-
tinuous with the retinal pigment epithelium, and of a non-
pigmented layer, which is continuous with the neuroretina 
[41, 92]. 
  Aqueous humor composition is considerably different 
from the plasma, from which the aqueous humor derives. In 
fact, the concentration of chlorides, lactates, sodium, uric 
acid, are greater in the aqueous humor than in plasma, and 
above all ascorbate, whose concentration is almost 70 times 
greater than in plasma. Whereas, iron, glucose, cholesterol, 
creatinine, calcium, bilirubin, tryglycerides and, particularly, 
total proteins are lacking in the aqueous humor [41]. It is 
produced in two different ways: active and passive secretion. 
Approximately 80% of aqueous humor is secreted by the non 
pigmented ciliary epithelium through an active metabolic 
process involving a number of enzymatic systems, the most 
important of which is Na
+/K
+ ATPase pump, which secretes 
Na
+ ions into the posterior chamber. A probable linkage of 
this system with an active transport of anions, such as chlo-
ride and bicarbonate, is suggested by the prominent action of 
the carbonic anhydrase inhibitors on the rate of formation of 
aqueous humor, and also by the short-circuit studies of Hol-
land and Gipson, which indicated that a part of the net flux 
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this ion [8, 11, 55, 76]. The remaining 20% of aqueous is 
produced by passive processes, such as ultrafiltration and 
diffusion, which depend on the level of blood pressure in the 
ciliary capillaries, the plasma oncotic pressure and the level 
of IOP. With reference to this, it is important to remember, 
for an example, that when IOP increases, the rate of aqueous 
humor secretion diminishes [13]. Aqueous humor exerts sev-
eral functions, the most important of which can be identified 
in the followings: (i) hydrostatic function, as it determines 
the ocular pressure which, in turn, optimizes optical func-
tions; (ii) optical function, as the aqueous humor maintains 
both the cornea’s curvature and the refractive index of the 
corneal stroma; (iii) nutritional function for the cornea and 
the lens, as a carrier of nutrients and drawing off their meta-
bolic end products; (iv) immunologic defense function, as a 
carrier of antibodies and drugs [127]. 
  Aqueous humor flows from the posterior chamber 
through the pupil into the anterior chamber and then into the 
trabecular meshwork (Fig. 4). The meshwork is essentially a 
filter that functions as a one-way valve. The ciliary muscle 
has insertions on the meshwork and ciliary contraction helps 
pump aqueous through the mesh, increasing the rate of 
drainage. In the irido-corneal angle of the anterior chamber, 
the aqueous enters the canal of Schlemm and then drains into 
episcleral veins. Small amounts of aqueous humor also leave 
the eye between the bundles of the ciliary muscle and 
through the sclera. Thus, aqueous humor leaves the eye by 
two routes: mainly, through the trabecular meshwork and 
Schlemm’s canal (conventional outflow), and secondary, 
through the anterior uvea (unconventional outflow) which, 
under normal circumstances, accounts for about 20% of the 
total outflow facility [8, 11, 41, 76, 92]. 
  The level of IOP is determined by the balance between 
the rate of aqueous humor production (inflow) and the resis-
tance that it encountered in the outflow pathways. If all these 
mechanisms working well, the fluid produced inside the eye 
equals the amount of fluid leaving the eye, and the resultant 
IOP is normal. Any alteration in the physiology of aqueous 
humor formation and drainage affects the IOP either increas-
ing or diminishing its level. Thus, the factors able to affect 
IOP are: (i) rate of aqueous humor secretion; (ii) resistance 
encountered in outflow channels; (iii) pressure at the level of 
the episcleral venous. The relationship between these factors 
is expressed by the Goldmann equation as follows: 
Po = (F/C) + Pe 
where Po = IOP (mmHg); F = rate of aqueous humor forma-
tion (μl/min); C = facility of aqueous humor outflow (μl/ 
min/mmHg); Pe = episcleral venous pressure (mmHg) [52]. 
  In the normal population mean IOP shows a Gaussian-
like distribution curve skewed to the right. Mean IOP in-
creases with age and is slightly higher in men (15.14 mmHg) 
than in women (14.94 mmHg) [16]. There is a wide range of 
IOP in normal population. Within this normal range, the up-
per of the IOP spectrum (20 mmHg) may be twice as high as 
the lower end of the spectrum (10 mmHg). Both values rep-
resent statistically normal pressures. Although there is not 
absolute cutoff point, 21 mmHg is generally considered as 
the upper limit of normal and values above this level are 
considered suspicious. In humans, has also been described a 
circadian slight, but significant, variation in IOP values, 
which are in general highest in the early morning and lowest 
during the night [41]. The amplitude of this fluctuation is 
small, ranging from 2 to 5 mmHg [114]. According to Eric-
son the phenomenon is due to a diurnal variation in the rate 
of secretion of fluid [47]. In fact, normal subjects have an 
increased probability of low IOP during the night and peaks 
at 4:00 a.m. and at the midnight, whereas between 8:00 a.m. 
and 8:00 p.m. the probability of occurrence of IOP changes 
is fairly low [72]. This means that an IOP value obtained 
from only one measurement throughout 24 hours is not suf-
ficiently probative for a sure diagnosis. Thus, in passing 
from the physiology to the pathology of IOP, we are intro-
ducing certain concepts about glaucoma. This eponym is 
commonly used to define a wide range of diseases, which 
traditionally include conditions associated with increased 
IOP. In fact, classically, glaucoma is defined as "an eye dis-
ease ... characterized by increased IOP, excavation and de-
generation of the optic disc, and typical nerve fiber bundle 
damage, producing defects in the field of vision" [15]. Actu-
ally, the glaucomatous disease is best defined as "... a related 
group of clinical syndromes characterized by damage of the 
optic nerve and loss of visual function obeying a character-
ized pattern usually associated with a statistically defined 
elevated IOP" [15]. Otherwise, it has been ascertained that in 
glaucomatous patients the reached IOP values exceed those 
individually tolerated by the optic nerve head; the inclusion 
of this important concept has resulted in a new definition of 
the disease: "glaucoma means a condition in which the optic 
nerve is damaged by IOP higher than the eye can tolerate" 
[15]. Although not all patients with glaucomatous optic neu-
ropathy (GON) have an increased IOP and not all subjects 
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with IOP elevation are affected by GON, the increased IOP 
remains the most important risk factor for its development 
[49]. The European Glaucoma Society has defined glaucoma 
as a etiologically heterogeneous group of ocular disorders 
characterized by the presence of an axon damage at the gan-
glion cells level, which lead to: (i) retinal nerve fiber layer 
alterations; (ii) optic nerve head cupping; (iii) typical visual 
field defect [48]. 
  In the natural history of glaucoma, the progression of 
visual field loss is a direct consequence of GON. Two op-
posed pathogenetic hypotheses have been claimed to explain 
the peculiar glaucomatous findings (optic nerve head 
changes and visual field deterioration): a direct mechanical 
theory and an indirect vascular theory. In the first, the in-
creased IOP directly damages the lamina cribrosa and neural 
axons. The second theory postulates that GON is the conse-
quence of insufficient blood supply to the optic nerve either 
due to increased IOP or other pathologic conditions which 
impair the ocular microcirculation. The hemodynamic condi-
tions, both systemic and local, affecting the microvascular 
structure, represent the second major risk factor, after in-
creased IOP, involved in the progression of the GON and 
visual dysfunction [49, 144]. The blood supply to the eye 
derives primarily from the first branch of the internal carotid 
artery: the ophthalmic artery. In the orbit it branches into the 
central retinal artery, one to five posterior ciliary arteries and 
several anterior ciliary arteries. The main part of the choroid 
is supplied by the short posterior ciliary arteries, whereas 
anterior ciliary arteries supply part of the peripheral choroid 
and the anterior uvea [59, 94]. Blood supply to the optic 
nerve head is very unique. From the anterior to the posterior 
tract, it is possible to distinguish four regions: (i) the surface 
nerve fiber layer receives blood from retinal arterioles; (ii) 
the prelaminar region, between the previous one and the lam-
ina cribrosa, is mainly supplied by the fine centripetal 
branches from peripapillary choroid; (iii) the lamina cribrosa 
region is entirely supplies by centripetal branches of the 
short posterior ciliary arteries; (iv) the retrolaminar region, 
immediately behind the lamina cribrosa, which receives both 
a centripetal (the pial vascular plexus, supplied by the Haller 
and Zinn circle which in turn, is formed by the short poste-
rior ciliary arteries) and a centrifugal blood supply (deriving 
from branches of the central retinal artery). This description 
makes evident that the main source of blood supply to the 
optic nerve head is due to the posterior ciliary arteries circu-
lation, which are obviously the only involved in the GON 
occurrence (Fig. 3) [61]. 
  A very simple classification of glaucoma, based on the 
fashion by which aqueous humor outflow is impaired, results 
in the distinction between open-angle or angle-closure glau-
coma, yet divided into primary and secondary forms, accord-
ing to the pathogenetic mechanisms responsible for their 
occurrence (Fig. 4). If the impairment of aqueous humor 
outflow is due to the presence of other ocular diseases (vas-
cular obstruction, inflammation, tumor) the glaucoma is 
called secondary. In the absence of such specific causes, the 
glaucoma is called primary, either of angle-closure or open-
angle type. Primary open angle glaucoma (POAG) is defined 
idiopathic because its peculiar pathogenetic mechanisms are 
yet unknown. Angle-closure glaucoma refers to the type in 
which the peripheral iris obstructs aqueous humor outflow 
by closing the irido-corneal angle [130]. In angle-closure 
glaucoma, as well as in congenital and secondary glaucomas, 
the cause/effect relationship between increased IOP and 
GON is clearly comprehensible. In fact, in these forms, the 
mechanical theory exhaustively explains how increased IOP 
alone leads to GON development: the elevated pressure is 
responsible for a progressive compression and posterior dis-
placement of the lamina cribrosa (a complex, reticulated 
elastic tissue which normally supports the optic nerve head 
and through which 1-2 million retinal ganglion cell axons 
leave the eye to form the optic nerve). The axoplasmatic 
transport is impeded, directly inducing cell death [118]. 
However, also in these forms, a synergism between me-
chanical and vascular effects may occur, because increased 
IOP, reducing blood supply to the optic nerve, simultane-
ously decreases the trophic factors availability, which also 
induce tissue ischaemia and cell death [49]. When IOP is 
only slightly elevated or even normal, like in most of the 
POAG patients or in normal tension glaucoma, it becomes 
more difficult to explain the GON occurrence only as de-
pendent by IOP. A wide range of important epidemiological 
conditions able to make the optic nerve vulnerable, or more 
vulnerable, to a given IOP level have been identified. This 
susceptibility of the optic nerve head increases with age, 
with genetic make up (race and family history both are risk 
factors) and with certain diseases able to impair the blood 
flow, known to constitute the so-called vascular risk factors 
[49, 60]. 
  Both high and low systemic blood pressure have been 
indicated as risk factors for GON development. A clear and 
significant relationship between glaucomatous damage and 
systemic hypotension has been documented, in particular 
with episodes of nocturnal arterial hypotension. Although 
these episodes are obviously expected in diseases character-
ized by systemic hypotension, they also occur in glaucoma-
tous patients treated for systemic hypertension, and at a rate 
highest than that estimated [63, 70]. Therefore, as we have to 
search for IOP peaks, we have also to search for blood pres-
sure dips. The immediate consequence of this event has been 
the need to introduce a new investigation in glaucomatous 
patients: the 24-hour monitoring of blood pressure, to know 
the real weight of this risk factor in the pathogenesis of GON 
[33, 38]. 
  Atherosclerosis is recognized as the chief cause of death 
in the United States and Western Europe, being the major 
culprit for cardiovascular and cerebral accidents. It occurs 
very frequently, and begins in childhood [133]. Atheroscle-
rosis commonly involves the large arteries, although the as-
sociation with central retinal artery occlusion and anterior 
ischemic optic neuropathy (diseases involving small size 
arteries) has been well-documented. The lesion is character-
ized by endothelial injury, proliferation of smooth-muscle 
cells, deposition of lipid material (atheromata) under the 
intima, followed by connective tissue proliferation. On the 
altered vessel surface platelet accumulation easily occurs, 
and thrombus may form [49, 60]. The vascular endothelium 
plays an active role in vasomotor function of both macro- 
and micro-vasculatures, including the maintenance of vascu-
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results from a balance between the concentration of vasodila-
tor (e.g. nitric oxide) and vasoconstrictor (e.g. endothelin) 
compounds at the level of the endothelial cells. In atheroscle-
rosis the endothelium dysfunction leads to the following 
schematic events: (i) defective dilatation of affected vessels; 
(ii) accentuated response to vasoactive products released by 
activated platelets, like serotonin; (iii) increased degradation 
of nitric oxide, which further impairs vasodilatation [60]. 
Thus, numerous factors may affect the blood perfusion 
through an organ, e.g. optic nerve head; among them, auto-
nomic nervous system, circulating hormones and endothelial 
cells layer seem to play the most important role in this regu-
lation. This very complex regulation might be easily altered 
by a lot of local or systemic conditions, which lead to an 
inadequate arterial constriction or dilation when needed. This 
phenomenon is termed vascular dysregulation or vasospasm 
[49]. 
  The vascular dysregulation synergistically acts together 
with increased IOP, or with an IOP level higher than the eye 
can tolerate, reducing the ocular perfusion. On the other 
hand, as already demonstrated for nitric oxide, the some 
compounds responsible for vascular dysregulation might also 
affect IOP [40, 143]. 
4. EFFECT OF SSRIS ON THE INTRAOCULAR 
PRESSURE AND THEIR POSSIBLE ROLE IN THE 
DEVELOPMENT OF OPTIC NEUROPATHY 
  The presence of 5-HT receptors in the iris-ciliary body 
complex (ICB), together with the presence of serotonin and 
its metabolites (5-hydroxyindolacetic acid and 5-hydroxy-
tryptophol) in aqueous humor, give evidence for a role of 
this amine in the regulation of aqueous humor dynamics. 
Experimental studies have ascertained that 5-HT1A, 5-
HT2A/2C and 5-HT7 receptors are located at the level of ICB 
[10, 28, 85, 98, 136, 137]. SSRIs increase the serotonin 
availability for these receptors, which react as though they 
were stimulated by agonists. Thus, the knowledge of each 
receptor function make possible to understand, with less dif-
ficulties, what happen when increased levels of endogenous 
serotonin reach the structures of anterior and posterior 
chambers of the eye (Fig. 3). 
  To date, only the 5-HT7 receptors have been identified at 
the iris level. These serotonergic receptors, when stimulated 
by agonists, are responsible for the sphincter muscle relaxa-
tion [28]. This dynamic pupillary action is also confirmed by 
the observation that metergoline and methysergide, both po-
tent 5-HT7 receptors antagonists, even cause passive mydria-
sis [3, 91]. In eyes with primary or secondary peculiar struc-
tural configuration of the irido-corneal angle (elevated hy-
peropia, steeply convex peripheral iris insertion, regularly 
straight iris with narrow angle, exfoliation syndrome, ciliary 
muscle hyperplasia, iris and ciliary body cysts, abnormality 
in shape and/or dimension of the lens, etc.), i.e. with a bio-
metric predisposition, the further reduction in width of irido-
corneal angle induced by mydriasis, may block the aqueous 
circulation, with the possible development of intermittent 
angle closure or acute angle-closure glaucoma (Fig. 4) [120]. 
 The  5-HT1A receptors selective agonism reduces IOP; 
cyclic AMP concentration, responsible for a reduced rate of 
aqueous humor production, within the epithelial cells (pig-
mented and non-pigmented) diminishes [117]. The seroton-
ergic effect on this receptor subtype is counterbalanced by a 
concomitant agonism exerted on the 5-HT7 receptors, which 
induces a cAMP elevation within the epithelial cells, with an 
increase of aqueous humor production [28]. The simultane-
ous stimulation of both 5-HT1A and 5-HT7 receptors, with 
opposing effects on adenylate cyclase in the same cell layer, 
is not expected to modify IOP. On the contrary, the admini-
stration of 5-carboxamidotryptamine, a 5-HT1A/5-HT7 ago-
nist, increases IOP [36, 84, 98], suggesting that, perhaps, its 
serotonergic action is lopsided towards the 5-HT7 receptors. 
 The  5-HT2A/2C receptors are also expressed in the ICB. 
The agonism on these subtype receptors presumably in-
creases the ciliary body blood flow, amplifying the metabolic 
activities of the ciliary processes, with an enhanced produc-
tion of aqueous humor. Recently, Tian and co-workers have 
demonstrated that 1-(2, 5-dimethoxy-4-iodophenyl)-2-amino-
propane, a 5-HT2 receptor agonist, grows both urine volume 
and urinary Na
+ excretion, secondary to renal vasodilatation 
[135]. Although the repercussion of 5-HT2 agonism on IOP 
has not yet been investigated, this mechanism could repre-
sent one of the most plausible to explain another way by 
means SSRIs increases IOP [37, 87]. In fact, recently, it has 
been demonstrated that intravenous administration of fluoxe-
tine significantly raises IOP in rabbits. This effect occurs via 
serotonin plasma levels augmentation, confirmed by elevated 
excretion of 5-hydroxyindolacetic acid in urine, and is 
strongly inhibited by topical administration of ketanserin, 
one of the most selective 5-HT2A receptors antagonist [51, 
64, 66, 87]. The answer of the ciliary body to a direct (via 5-
HT7 receptors) or an indirect (via 5-HT2A receptors) stimula-
tion activity consists in an increase of the aqueous humor 
inflow. When the outflow pathway are not able to drainage 
the aqueous humor overproduction IOP shall raise, according 
to the Goldmann equation [52]. On the other hand, IOP it-
self, triggering a negative feedback on the aqueous humor 
secretion, is able to exert an inflow autoregulation, which 
accounts for about 20% of aqueous humor production (pas-
sive ultrafiltration) [41]. The empirical correlation of this 
statement is in the evidence that fluoxetine administration to 
patients surely unaffected by glaucoma causes a transient 
21.95% IOP increase from baseline, followed by a came 
back to the pre-treatment values in few hours [37]. This 
event has been observed in young adult depressed, otherwise 
healthy, subjects after the first exposure to SSRIs, but no 
data are actually available regarding the long-term effect of 
these compounds on IOP. In other words, it has not yet been 
established whether the chronic assumption of SSRIs is re-
sponsible for a iatrogenic IOP shift towards highest levels, 
with a consequent overload of the autoregulation system. 
This last mechanism can work by influencing only the F 
component of the Goldmann equation (rate of aqueous hu-
mor formation), whereas it is well known that the role played 
by the C component (facility of aqueous humor outflow), 
which decreases with aging, is also crucial for the IOP 
modulation. After SSRIs intake the ocular autoregulation 
system is able to ensure an equilibrium among the compo-
nents affecting IOP homeostasis in the most part of de-
pressed patients. This probably occurs just in the youngest 
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plaque material at the level of the cribriform layer of the 
trabecular meshwork, derived from the sheaths of the elastic-
like fibers, increases with age, inducing a parallel physio-
logical increase in the outflow resistance. Moreover, in com-
parison to normal eyes, this material is significantly greater 
in cases of POAG and of intermittent narrow-angle glau-
coma [83], suggesting that the enhanced resistance to the 
outflow observed in elderly patients and, at highest extent, in 
the subjects suffering from the two above mentioned forms 
of glaucoma, represents one of the mechanism leading to 
IOP increase. These mechanisms, at least theoretically, ex-
plain how the SSRIs intake can affect the IOP homeostasis 
and how the IOP ocular autoregulation system in elderly 
subjects, such as - independently from age - in glaucomatous 
patients or in eyes with primary or secondary peculiar struc-
tural configuration of the irido-corneal angle, could be not 
able to ensure the maintenance of IOP within individual ac-
ceptable physiological limits. 
  In 1991, Ahmad firstly described a 35-year-old man with 
acute angle-closure glaucoma occurred after five-week oral 
fluoxetine administration [4]. To date, other similar dramatic 
observations secondary to the intake of this specific SSRI 
have not been recorded. However, six cases of angle-closure 
glaucoma attack, induced by paroxetine administration, have 
been reported in the Literature [12, 18, 46, 71, 79, 80]. In the 
first three case reports, this adverse ocular reaction occurred 
in patients whose ages ranged from 70 to 91 years, an atypi-
cal life-period for the occurrence of acute-angle glaucoma, as 
confirmed by epidemiological studies [16]. In these elderly 
phakic patients, the lens status per se, in presence of an ocu-
lar biometric predisposition, synergistically interacting with 
paroxetine-induced passive mydriasis (via 5-HT7 receptors), 
easily can determine the glaucomatous attack [46, 71, 80]. 
The other three cases were observed in younger subjects with 
normal lens, but affected by hyperopia [12, 18, 79], an ascer-
tained risk factor for intermittent angle closure or acute an-
gle-closure glaucoma [120]. The interval between the onset 
of paroxetine administration and the development of the ocu-
lar adverse reaction was fairly different among these pa-
tients, ranging from few days to several weeks. There is only 
one case of acute attack of glaucoma reported in the Litera-
ture secondary to the use of fluvoxamine [69]. In this 66-
year-old woman with a narrow-angle glaucoma, the exacer-
bation of the ocular disease became evident immediately 
after she started the antidepressive treatment. The two cases 
reported after citalopram administration have occurred in 
relatively young women, who were unaffected by neither 
cataract nor hyperopia [39, 86]. The mechanisms by which 
citalopram has been responsible of the acute attack has not 
been completely ascertained. Nevertheless, it may be possi-
ble that these patients were predisposed to the development 
of a glaucoma’s acute attack due to unknown inherent fac-
tors. About the causal relationship, it could be proposed that 
citalopram may directly act on the iris or ciliary body muscle 
through serotonergic or cholinergic mechanisms, or both. 
Lastly, a case of a 41-year-old woman who developed acute 
bilateral angle closure glaucoma with choroidal effusions 
while receiving escitalopram therapy has been recently de-
scribed [145]. Medication-induced uveal effusion causing 
angle closure has been well documented with the antiepilep-
tic medication topiramate [50], and in this case the mecha-
nism appears to be similar. In fact, the ultrasonographic find-
ings of choroidal effusion with ciliary body detachment dur-
ing the acute attack with resolution of these findings once the 
attack was broken provide clear evidence that the mechanism 
of bilateral angle closure was related to uveal effusion. To 
date, no similar adverse events have been still documented 
after the administration of sertraline, although a significant 
increase in pupil diameter after administration has been docu-
mented with the use of these compounds. Mydriasis occurs 
quite rapidly following a single acute dose of sertraline, 
reaching a maximum 5 h after first administration. Subse-
quently, mydriasis remained stable at this level throughout 
the treatment period [123, 125]. In all these case reports, the 
Authors emphasized the role of passive mydriasis as precipi-
tating event in the determinism of the acute angle-closure 
glaucoma [4, 12, 18, 39, 46, 69, 71, 79, 80, 86, 145]. The 
greater number of angle-closure glaucoma attacks reported 
with paroxetine, as compared to the other SSRIs, may be due 
to its relatively low IC50 value for the noradrenaline uptake 
(Table  3). In fact, the sympathomimetic noradrenergic ac-
tion, stimulating the dilator pupil muscle, produces an active 
mydriasis which, together with the serotonergic passive one, 
is able to reinforce the crowding at the level of the irido-
corneal angle. This triggering mechanical phenomenon can 
Table 3.  Pharmacologic Properties of the SSRIs: Their Effect on the Uptake of Biogenic Amines in Vitro (Adapted from: Hyttel J, 
1994; Burke WJ & Kratochvil CJ, 2002) [160, 167] 
Monoamine Uptake Inhibition, IC50 value (nM) 
SSRI 
Serotonin Noradrenaline Dopamine 
IC50 NA Uptake / IC50 5-HT 
Uptake 
Fluoxetine 6.8  370  5000  54 
Sertraline 0.19  160  48  840 
Paroxetine 0.29  81  5100  280 
Fluvoxamine 3.8  620  42000  160 
Citalopram 1.8  6100  40000  3400 
Escitalopram 1.5  2500  65000  1700 Selective Serotonin Reuptake Inhibitors  Current Neuropharmacology, 2008, Vol. 6, No. 4    305 
bring iris tissue into closer proximity with the functional 
trabecular meshwork, the structure that normally allows 
aqueous humor to escape from the eye. For this reason, the 
use of TCAs, nonselective antidepressants, known to possess 
an evident noradrenergic action, is absolutely contraindicated 
in subjects with congenital and/or acquired predisposition to 
intermittent, sub-acute or acute angle-closure glaucoma [74, 
81, 111, 120]. All data concerning the IOP modifications 
induced by SSRIs are summarized in Table 4.  
  The incidence of ocular side effects induced by SSRIs is 
probably underestimated because the IOP increase in the 
course of intermittent angle closure and, some more, in mis-
diagnosed forms of POAG is, respectively, pauci- or asymp-
tomatic. Thus, it is not quite hazardous to hypothesize that 
the significant incidence of unspecified visual disturbances, 
reported by Preskorn in a comparative study on SSRIs toler-
ability [69], could be attributed - at least in some cases - to 
IOP modifications. This percentage probably comprises: (i) 
IOP impairments, related to intermittent angle closure or, 
more rarely, to episodes of marked IOP increase in patients 
with misdiagnosed POAG; (ii) acute reduction of retinal or 
optic nerve head blood supply, secondary to hemodynamic 
changes (vasoconstriction and/or platelet aggregation) at the 
level of central retinal artery or posterior ciliary arteries, re-
spectively; (iii) locally vessel size dysregulation related to 
vasospasm of the ophthalmic artery in case of migraine with 
visual aura [37, 49, 60]. In clinical practice, during a antide-
pressive SSRIs treatment, the above mentioned modifica-
tions of the aqueous humor and/or blood dynamics are diffi-
cult to diagnose as much as to predict, because the real 
plasma concentration of both parent drug and its metabolites 
has a significant inter-individual variability. In fact, peculiar 
genetic mosaicism of cytochrome P450 (CYP) enzymes 
and/or several acquired pathophysiologic conditions, affect-
ing the detoxifying processes, are able to delay the SSRIs 
biotransformation and elimination, prolonging their seroton-
ergic effects in an unforeseeable fashion (individual peculiar 
SSRIs tolerability) [7, 23, 55, 141, 142]. 
Table 4.  Summary of the Reports Describing SSRIs-Induced IOP Modifications 
Author SSRI  Administered  Patient’s   
Age and Sex 
Side Effect  Interval from the Admini-
stration 
Ahmad S. [4]
  Fluoxetine  35-year-old man  Acute angle closure glaucoma   Five weeks 
Costagliola C,  
et al. [37]
 
Fluoxetine  male: female 5:15  
age range 33 – 47 years 
IOP increase  
in both eyes 
Two hours 
Kirwan JF,  
et al.
 [71] 
Paroxetine  91-year-old woman  Bilateral acute  
angle closure glaucoma 
One day 
Lewis CF,  
et al. [80] 
Paroxetine  70-year-old man  Acute angle closure glaucoma  Three days 
Eke T,  
Bates AK. [46] 
Paroxetine  84-year-old woman  Acute angle closure glaucoma  Two weeks 
Bennett HG,  
Wyllie AM. [12] 
Paroxetine   53-year-old woman  Acute angle closure glaucoma  Three days 
Browning AC,  
et al. [18] 
Paroxetine  40-year-old man  Acute angle closure glaucoma  Two weeks 
Levy J,  
et al. [79] 
Paroxetine   54-year-old woman  Late bilateral angle closure 
glaucoma 
Two months 
Jimenez-Jimenez FJ,  
et al. [69] 
Fluvoxamine  66-year-old woman  Aggravation of narrow-angle 
glaucoma 
One day 
Croos R,  
et al. [39] 
Citalopram   54-year-old woman  RE: ocular hypertension 
LE: acute angle closure glaucoma 
Soon after Citalopram and 
alcohol overdose 
Massaoutis P,  
et al. [86] 
Citalopram   55-year-old woman  Bilateral acute  
angle closure glaucoma 
Three months 
Zelefsky JR,  
et al. [145] 
Escitalopram   41-year-old woman  Bilateral angle closure glaucoma.  Four weeks 306    Current Neuropharmacology, 2008, Vol. 6, No. 4  Costagliola et al. 
  Increased plasma levels of serotonin may be a factor or, 
more probably, a co-factor in the development of optic nerve 
head perfusional disorders, either synergistically with an IOP 
level higher than the eye can tolerate (individual critical IOP) 
or independently from IOP with a direct vascular dysfunc-
tion of the posterior ciliary arteries. In the course of chronic 
antidepressive treatment with SSRIs, multiple transient vaso-
spasms at the level optic nerve head vessels may directly 
produce hemodynamic alterations that, time to time, could 
progressively induce a manifest optic ischemic neuropathy. 
In atherosclerotic individuals, the susceptibility to develop 
this kind of vascular disorder becomes highest because sero-
tonin, enhancing platelet aggregation on the atheromata, can 
also indirectly trigger vasospasm of ocular arteries [60]. At 
the level of brain microcirculation it has been ascertained 
that serotonin is implicated in its regulation; significant 
changes in the status of 5-HT neurons of SNC have, in fact, 
vascular repercussion in specific brain regions. This implies 
that neuronal serotonin release constitutes the basis of nor-
mal blood flow regulation that, when dysfunctional, may 
lead to inadequate blood supply to the brain [31]. In coronary 
arterial district, the role of serotonin in vasoconstriction or 
even vasospasm has been recently indicated as possible co-
factor in the occurrence of myocardial ischemia in patients 
with acute coronary syndromes [53]. In fact, some cases of 
vasospastic angina do not achieve response to the conven-
tional treatment (Ca
2+ antagonists, nitrates and K channel 
opener), whereas the association with serotonergic receptor 
blockade reduces anginal attack, suggesting that the vaso-
spastic disorder is partially caused by serotonin [128]. The 
recently recorded escitalopram-induced uveal effusion [145] 
and sertraline presumed maculopathy [128] may be due to 
this blood flow dysfunction secondary to SSRIs administra-
tion.  
  Although AACG is an uncommon disease, risk factors 
have been identified. Women are more likely to develop 
AACG than men. Persons older than 50 years are at slightly 
increased risk, as are individuals with hyperopia. Those with 
a personal or family history of angle-closure glaucoma are at 
increased risk for the disease. Finally, people of Eskimo or 
Asian descent have higher rates of AACG [17]. The reported 
AACG attacks secondary to SSRIs administration have been 
more frequent in women than in men (8:3; 72%:28%; 
women:men) (Table 4). There are some evidences support-
ing this datum: i) peripheral anterior chamber depth is less 
wide in women than in men and, with aging, it tends to be 
progressively reduced; ii) the different prevalence of depres-
sion between the two sexes, with a 2:1 female: male ratio in 
adulthood [68]. Moreover, independently by sex, hyperopic 
eyes have a predisposition to a reduced wide of the angle, 
with a consequent enhanced risk for glaucoma acute attack 
[17, 32].  
  Lastly, SSRIs intake has been associated with the syn-
drome of inappropriate antidiuretic hormone secretion 
(SIADH) and hyponatremia [77]. The frequency of hypona-
tremia is around 8 per 1, 000 among elderly women. The risk 
of developing hyponatraemia, a potentially fatal condition 
that is typically asymptomatic until it becomes severe, ap-
pears to be highest during the first few weeks of treatment. 
SIADH is more likely in some populations, including people 
who are elderly or who take diuretics [120]. A dose-depen-
dent elevation of IOP has been reported in rabbits after injec-
tions of vasopressin into the 3(rd) ventricle. This IOP eleva-
tion was blocked by the pretreatment with the V(1) receptor 
antagonist. Thus, a third mechanism by which SSRIs might 
affect IOP could be dependent by the central effect of ADH 
on IOP via stimulations of the V(1) receptors, without affect-
ing pupil diameter [54]. 
CONCLUSION 
  In the clinical practice, the currently available SSRIs rep-
resent the most widely utilized medical therapy in patients 
affected by depression and/or other heterogeneous mood and 
anxiety disorders. A worldwide prospective analysis revealed 
that, during the next two decades, the incidence of these psy-
chiatric diseases in the general population is destined to pro-
gressively grow [93]; thus, unavoidably, the agreeable effec-
tiveness-tolerability-safety profile of the SSRIs will result in 
a more extensive prescription of these antidepressants by 
psychiatrists and also non-psychiatrists. Until the real in-
volvement of SSRIs on IOP increase and optic nerve head 
changes shall not be well-ascertained, it is difficult to draw 
final conclusions on the more reasonable clinical manage-
ment of depressed patient under SSRIs treatment. The 
knowledge of individual tolerability, angle-closure predispo-
sition and critical IOP could be goals no so difficult to real-
ize. In fact, although in the course of a search utilizing Med-
line, we have found only eleven papers documenting cases of 
acute angle-closure glaucoma related to SSRIs administra-
tion [4, 12, 18, 39, 46, 69, 71, 79, 80, 86, 145], the World 
Health Organization Adverse Drug Reactions database con-
tains several other reports of undefined glaucoma associated 
with the different marketed SSRIs. This discrepancy further 
confirms the suspicious that the recording of pauci- or as-
ymptomatic side effects, like POAG, is underestimated. 
Thus, because experimental and clinical findings indicate 
that SSRIs affect pupil diameter, aqueous humor dynamics 
and optic nerve blood flow, the following recommendations 
should be taken into account: 
i.  in presence of ascertained glaucomatous risk factors (sex, 
race, positive familial history for glaucoma, mid or high 
hyperopia, cataract, etc.) is ethic to submit the patient to 
an ophthalmologic consultation, before the starting of the 
SSRIs treatment; 
ii. in elderly patients, before the starting and during the 
SSRIs treatment, serum electrolytes, and periodical IOP 
measurements should be prescribed; in presence of 
hemorheologic risk factors, specific examinations (i.e. 
computerized automated perimetry performed with dif-
ferent peculiar strategies and scanning laser Doppler 
flowmetry of the optic nerve head) should be, at least, 
advised. 
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